US based but China focused small cap biopharmaceutical stockCASI Pharmaceuticals (NASDAQ: CASI) is up around 78% over the last three trading days on no apparent news on the newswires as the following chart illustrates:
CASI Pharmaceuticals is a U.S. based, late-stage small cap biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. The Company’s product pipeline features
EVOMELA庐, MARQIBO庐 and ZEVALIN庐, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory and clinical process for market approval in China Proprietary drug candidate, ENMD-2076, ongoing in one Phase 2 clinical study CASI-001 and CASI-002, proprietary preclinical candidates in immune-oncology.
The Companyis headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China.
Hot Small Cap Stocks For 2018: Square, Inc.(SQ)
- [By Spencer Israel]
You can listen to the show live every day from 8-9 a.m. ET here, or catch the podcast on iTunes, Soundcloud and Stitcher.
Marvell Technology Group Ltd. (NASDAQ: MRVL): $19.75 has been the low since the deal was rumored so that’s support. Below that ,there’s a gap down to $18.55.
Alibaba Group Holding Ltd (NYSE: BABA) has a pair of highs near $188. The premarket high was $188.07 and there are similar highs from Nov. 8 and 13, so that whole handle will be resistance.
Square Inc (NYSE: SQ): It’s at all-time high levels right now. There’s support at Friday’s close at $44.18.
Twitter Inc (NYSE: TWTR): The Dorsey sympathy move is on. The Nov. 1 high of $20.99 and post-earnings high of $21.96 are two resistance levels.
General Electric Company (NYSE: GE): Has a double top from the last two sessions at $18.47 and $18.48.
Watch the full show below!
- [By Chris Lange]
Square Inc. (NYSE: SQ) is set to release its most recent quarterly results Wednesday. The consensus estimates are a net loss of $0.05 per share, as well as $536.27 million in revenue. Shares ended the week at $26.20. The consensus price target is $23.81, and the 52-week range is $9.85 to $27.97.
- [By Elizabeth Balboa]
Western Digital Corp (NASDAQ: WDC) lost 16 percent over the last eight trading sessions, and Square Inc (NYSE: SQ), after a 264-percent run, conceded 24 percent.
- [By ]
Payment processors and banks that are allowing bitcoin exchange are also benefiting as first-movers in digital transactions. It’s likely that most payment processors will integrate some cryptocurrency capability eventually but the first-mover advantage for companies like Square (NYSE: SQ) should help it boost user growth over the next year.
- [By Travis Hoium]
2016 was a rocky year for Square Inc(NYSE:SQ), to say the least. At times, the market couldn’t tell whether the company was making a turn toward profitability or falling down a rabbit hole of losses it may never emerge from.
- [By Zacks]
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cisco Systems, Inc. (NASDAQ: CSCO): Free Stock Analysis Report
Amazon.com, Inc. (NASDAQ: AMZN): Free Stock Analysis Report
Facebook, Inc. (NASDAQ: FB): Free Stock Analysis Report
Alphabet Inc. (NASDAQ: GOOGL): Free Stock Analysis Report
Square, Inc. (NYSE: SQ): Free Stock Analysis Report
PayPal Holdings, Inc. (NASDAQ: PYPL): Free Stock Analysis Report
QUALCOMM Incorporated (NASDAQ: QCOM): Free Stock Analysis Report
Microsoft Corporation (NASDAQ: MSFT): Free Stock Analysis Report
NVIDIA Corporation (NASDAQ: NVDA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hot Small Cap Stocks For 2018: New Residential Investment Corp.(NRZ)
- [By Lisa Levin]
Ocwen Financial Corp (NYSE: OCN) shares were also up, gaining 42 percent to $3.25. New Residential Investment Corp (NYSE: NRZ) revealed it owned some servicing rights to the troubled Ocwen Financial. During today's conference call, New Residential’s executive suggested the company will pay $425 million for Mortgage Servicing Rights to Ocwen.
- [By Chris Dier-Scalise]
Thge Vetr crowd upgraded its rating for New Residential Investment Corp (NYSE: NRZ) on Friday from the company's previous standing at 3 stars (Hold), issued 10 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.
- [By ]
New Residential (NYSE: NRZ) is a U.S.-based REIT that specializes in managing investments in residential real estate. With a market cap of $5.5 billion, NRZ is one of the largest REITs in the United States, so this is no fly-by-night company. NRZ offers one of the best dividends in the industry. The trust made four dividend payments in 2017 totaling $1.94. That gives shares a current yield of 11.3%, more than a 400% premium to the S&P 500’s average 2.0% yield.
- [By Sean Williams]
Today’s lawsuit has spilled over to the company’s peers as well. New Residential Investment Corp. (NYSE:NRZ), which invests in excess mortgage servicing rights (MSRs), wound up falling as much as 13% during the day’s trading session. Ocwen is one of the three companies mentioned as being one of the primary servicers in New Residential Investment’s MSRs, according to its 10-K. If mortgage owners or bondholders terminate Ocwen as the servicer, the excess MSRs tied to Ocwen could lose some or all of their value.Altisource Portfolio Solutions S.A.(NASDAQ: ASPS)fell 42%.
Hot Small Cap Stocks For 2018: Juniper Pharmaceuticals, Inc.(JNP)
- [By Jim Robertson]
On Monday, our Under the Radar Moversnewsletter suggested shorting women’s health stock Juniper Pharmaceuticals (NASDAQ: JNP):
Juniper Pharmaceuticals shares have yet to break under a key support level at $5.00. But, waiting until that happens may be too late. After some continued testing of that floor, if-and-when the support should break, the ensuing selloff could materialize in a hurry. If you’re not it at the time it happens, you may not be able to get in at a decent price.
- [By Jim Robertson]
On Thursday, our Under the Radar Moversnewsletter suggested shorting small cap women’s health therapeutic stock Juniper Pharmaceuticals (NASDAQ: JNP):